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Abstract
Background: Shoulder pain is reported to be highly prevalent and tends to be recurrent or persistent despite medical
treatment. The pathophysiological mechanisms of shoulder pain are poorly understood. Furthermore, there is little
evidence supporting the effectiveness of current treatment protocols. Although myofascial trigger points (MTrPs) are rarely
mentioned in relation to shoulder pain, they may present an alternative underlying mechanism, which would provide
new treatment targets through MTrP inactivation. While previous research has demonstrated that trained physiotherapists
can reliably identify MTrPs in patients with shoulder pain, the percentage of patients who actually have MTrPs remains
unclear. The aim of this observational study was to assess the prevalence of muscles with MTrPs and the association
between MTrPs and the severity of pain and functioning in patients with chronic non-traumatic unilateral shoulder pain.
Methods: An observational study was conducted. Subjects were recruited from patients participating in a controlled
trial studying the effectiveness of physical therapy on patients with unilateral non-traumatic shoulder pain.
Sociodemographic and patient-reported symptom scores, including the Disabilities of the Arm, Shoulder, and Hand
(DASH) Questionnaire, and Visual Analogue Scales for Pain were compared with other studies. To test for differences in
age, gender distribution, and education level between the current study population and the populations from Dutch
shoulder studies, the one sample T-test was used. One observer examined all subjects (n = 72) for the presence of
MTrPs. Frequency distributions, means, medians, standard deviations, and 95% confidence intervals were calculated for
descriptive purposes. The Spearman’s rank-order correlation (r) was used to test for association between variables.
Results: MTrPs were identified in all subjects. The median number of muscles with MTrPs per subject was 6 (active
MTrPs) and 4 (latent MTrPs). Active MTrPs were most prevalent in the infraspinatus (77%) and the upper trapezius
muscles (58%), whereas latent MTrPs were most prevalent in the teres major (49%) and anterior deltoid muscles
(38%). The number of muscles with active MTrPs was only moderately correlated with the DASH score.
Conclusion: The prevalence of muscles containing active and latent MTrPs in a sample of patients with chronic
non-traumatic shoulder pain was high.
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Background
Shoulder pain, which is often persistent or recurrent, is
one of the major reasons patients consult with primary
healthcare providers [1-6]. However, the pathophysiolo-
gical mechanisms underlying shoulder pain are poorly
understood. Although subacromial impingement is often
suggested to be a potential source of shoulder pain
[7,8], solid evidence is lacking. In fact, calcifications,
acromion spurs, subacromial fluid, or signs of tendon
degeneration are equally prevalent in healthy subjects
and in patients with shoulder pain [9-12]. Furthermore,
physical examination tests of subacromial impingement
are not reliable [13-15], and the results of imaging diag-
nostics do not correlate well with pain [9,10,16,17]. In
addition, interventions targeting subacromial problems
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shoulder complaints [18-24].
Myofascial trigger points (MTrPs) may offer an alter-
native explanation for the pathophysiological mechan-
isms underlying shoulder pain. In recent years, our
understanding of the etiology, pathophysiology, and
management of MTrPs has increased [25-30]. MTrPs
are local points, that are highly sensitive to pressure, the
application of which causes characteristic referred sensa-
tions, including pain, muscle dysfunction [26], and sym-
pathetic hyperactivity [31-33].
MTrPs are classified into active and latent myofascial
trigger points. Active MTrPs are characterized by the
presence of clinical pain and constant tenderness. Speci-
fically, active MTrPs prevent full lengthening and weak-
ening of the muscle. Diagnostically, active MTrPs refer
patient-recognized pain upon compression and mediate
a local twitch response in muscle fibers when stimu-
lated. When compressed within the patients’ level of
pain tolerance, active MTrPs produce referred motor
phenomena and often sympathetic hyperactivity, (gener-
ally in the pain reference zone), and cause tenderness in
the pain reference zone. In contrast, latent MTrPs are
clinically quiescent, and are only painful when palpated.
With the exception of spontaneous pain, a latent MTrP
can present with all the clinical characteristics of active
MTrPs. In addition, latent MTrPs are within a taut
band that increases muscle tension and restricts
patients’ range of motion [26]. Although the exact
pathophysiology of MTrPs is not yet fully understood,
abnormal electrical activity, called endplate noise, has
been associated with both latent and active MTrPs, and
several pain-inducing and pro-inflammatory substances
have been found at active MTrP in humans [27,34].
In clinical practice, identification of MTrPs is usually
performed by palpation. In a recent study [35], we con-
firmed that this technique is a reliable method for
detecting MTrPs in shoulder muscles. Although preva-
lence studies are sparse [36-42], based on clinical experi-
ence, MTrPs seem to be associated with shoulder pain,
disability, and dysfunction [43-45]. Still, little is known
about the impact of MTrPs onp a i na n df u n c t i o n i n gi n
patients with shoulder disorders [46]. Because MTrPs
refer pain to the shoulder, they may contribute substan-
tially to the clinical picture of shoulder pain (Figure 1, 2,
3 and 4). Experimental muscle pain, clinical muscle
pain, and MTrPs have all been shown to alter motor
activation patterns in a similar manner as the kinematic
disturbances seen in shoulder pain patients often
referred to as SIS [47-49].
The aim of this study was to determine the prevalence
of MTrPs and the correlation between MTrPs and pain
and functioning, in a sample of patients presenting with
chronic, non-traumatic unilateral shoulder complaints.
Methods
Study design
This observational study was embedded in a clinical trial
(registered at current controlled trials ISRCTN75722066)
addressing a specific treatment of patients with shoulder
pain [50]. The Committee of Human Research of the
region Nijmegen-Arnhem, the Netherlands, has approved
the study protocol [CMO 2007/22].
Study Participants
Study participants were recruited from patients partici-
pating in a controlled trial investigating the effectiveness
of physical therapy on patients with unilateral, non-trau-
matic shoulder pain. This study was conducted at a pri-
mary care practice for physical therapy, which
specializes in the treatment of patients with disorders of
the shoulder, the neck, and upper extremities. A power
analysis was performed prior to beginning this study,
and it was calculated that 104 subjects were needed for
the clinical trial.
All patients who contacted the practice for non-speci-
fic shoulder complaints from September 2007 until
Figure 1 Referred pain patterns (red) from the upper and
lower trapezius muscle MTrPs (Xs), according to Simons et al.
Illustrations courtesy of LifeART/MEDICLIP, Manual Medicine 1,
Version 1.0a, Lippincott, Williams & Wilkins, 1997.
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Page 2 of 12September 2009 were requested to participate in the
study. The inclusion criteria were 1) age between 18
and 66 years; 2) unilateral non-traumatic shoulder pain;
and 3) duration of symptoms of more than six months.
Patients were excluded from the study if they presented
with a prior diagnosis of shoulder instability, shoulder
fractures, any systemic diseases, or a medical history or
examination suggestive for the presence of neurological
disease, internal diseases, or psychiatric disorders. All
patients signed a written informed consent before parti-
cipating in the study.
General Applicability
To determine the potential general applicability of this
study to primary care shoulder pain patients, we
searched for Dutch studies conducted on primary care
patients from 1995 until 2009. Eight studies were found
and sociodemographic data (age, gender, education
level, and duration of shoulder pain) were analyzed and
compared to the current study population [2,5,51-55].
Measures
At baseline, age, gender, hand dominance, and educa-
tion level were recorded. For comparison reasons we
classified the education level as high education (univer-
sity and higher vocational school), medium education
(middle vocational school and higher or middle general
secondary school), and low education (lower vocational
school, lower general secondary school, primary school,
Figure 2 Referred pain patterns (red) from the upper and
middle trapezius muscle MTrPs (Xs), according to Simons et al.
Illustrations courtesy of LifeART/MEDICLIP, Manual Medicine 1,
Version 1.0a, Lippincott, Williams & Wilkins, 1997.
Figure 3 Referred pain patterns (red) from the anterior deltoid
muscle MTrPs (Xs), according to Simons et al. Illustrations
courtesy of LifeART/MEDICLIP, Manual Medicine 1, Version 1.0a,
Lippincott, Williams & Wilkins, 1997.
Figure 4 Referred pain patterns (red) from the infraspinatus
muscle MTrPs (Xs), according to Simons et al. Illustrations
courtesy of LifeART/MEDICLIP, Manual Medicine 1, Version 1.0a,
Lippincott, Williams & Wilkins, 1997.
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Page 3 of 12or no education) [54]. Shoulder-pain related data (dura-
tion of shoulder-pain, recurrence rate and location of
the complaints) were collected and the study subjects
were asked to complete a set of standardized self-report
measures, including the Disabilities of the Arm,
Shoulder, and Hand outcome measure - Dutch Lan-
guage Version (DASH-DLV), Visual Analogue Scale for
Pain (VAS-P) and the Beck Depression Inventory- Sec-
ond Version- Dutch Language Version (BDI-II-DLV)
[50]. The BDI-II-DLV is used to discriminate between
patients with major depression and those with only
minor depressive feelings or no depression, which may
be a confounding factor. The BDI-II has good predictive
value, is widely accepted, and is commonly used in both
clinical and experimental research. A BDI-II-DLV score
equally or ≥ 21 indicates major depression (specificity
78.4%) [56].
For every study participant, one of the two available
observers measured the passive range of motion
(PROM) of the shoulder in flexion, internal and external
rotation, abduction, and (horizontal or cross-body)
adduction with a handheld digital inclinometer (The
Saunders Group Inc, Chaska, MN). Range of motion
was expressed in degrees and presented as the sum of
the value measured for the non-affected shoulder minus
the value measured for the affected shoulder. A positive
value means that the affected shoulder had impaired
range of motion as compared to the non-affected
shoulder.
Next, the observer examined each subject for the pre-
sence of MTrPs in the shoulder muscles of their affected
shoulder according to the guidelines outlined in Simons
et al [26]; the non-affected s h o u l d e rw a se x a m i n e da sa
control. Following these guidelines, an MTrP is defined
as: a nodule in a taut band that is extremely painful
upon compression, and may produce referred pain or
sensations. MTrPs were classified as either ‘active’ when
the pain was recognized by the patient as a familiar
pain, and ‘latent’ when the observer found a firm nodule
in a taut band, which was painful on compression, but
did not produce a recognizable pain. The inter-examiner
reliability of trigger point palpation has been established
in several studies [35,57,58]. All 17 muscles that are
known to produce pain in the shoulder or may result in
dysfunction of shoulder muscles were systematically
examined and the number of muscles with MTrPs in
the affected shoulder was counted, regardless of the
number of MTrPs per muscle (Table 1). The two obser-
vers were physical therapists, each with 30 years of clini-
cal experience in primary care practice. Both observers
had attended an extensive, postgraduate course on
MTrP diagnosis and therapy and had more than 5 years
experience in identifying MTrPs and treating patients
with MTrPs prior to the start of the study.
The DASH-DLV is a widely used multidimensional
(physical, emotional and social) 30-item self-reporting
questionnaire that focuses on physical function, pain
and other symptoms. DASH-DLV scores ranges from 0
to 100, with higher scores indicating greater disability.
DASH is a reliable and valid questionnaire, with good to
excellent intra- and inter-rater reliability, and good cor-
relation with the Shoulder Pain and Disability Index.
Because of these advantages, DASH is considered to be
one of the best questionnaires available for shoulder
symptoms (http://www.dash.iwh.on.ca/) [59,60].
T h eV A S - Pi sas e l f - r e p o r ts c a l ec o n s i s t i n go fa1 0 0
mm horizontal line anchored by word descriptions on
each side [61]. VAS-P can be used to measure pain cur-
rent pain levels (VAS-P1), the average pain over the last
7 days (VAS-P2), and the most severe pain over the last
7 (VAS-P3)). VAS-P scores ranges from 0 (no pain) to
100 (the worst pain imaginable). The Visual Analogue
Scale has properties consistent with a linear scale for
patients with mild to moderate pain.
Data was collected and transferred to a worksheet by a
research assistant (who was not involved in the physical
examination or palpation of MTrP).
Data analysis
Frequency distributions, means, medians, standard
deviations, and 95% confidence intervals were calculated
for descriptive purposes. The Shapiro-Wilk W test was
used to test for normality of the data. Because the num-
ber of muscles with MTrPs (active, latent and total) was
not normally distributed we used the Spearman’sr a n k -
order correlation (r) test for all variables. For interpreta-
tion of the r-values, we used the classification proposed
by Feinstein [62]. A correlation coefficient < 0.30 was
considered to be indicative of a poor correlation. A cor-
relation coefficient ≥ 0.30 and ≤ 0.70 was considered to
be indicative of moderate correlation, and a correlation
coefficient ≥ 0.70 was defined as substantial or a good
correlation. To test for differences in age, gender distri-
bution, and education level between the current study
population and study populations from Dutch shoulder
Table 1 List of muscles examined for presence of MTrPs
upper trapezius
muscle
middle trapezius
muscle
lower trapezius
muscle
Infraspinatus muscle supraspinatus muscle subscapularis muscle
teres minor muscle teres major muscle anterior deltoid
muscle
middle deltoid muscle posterior deltoid
muscle
pectoralis major
muscle
pectoralis minor
muscle
biceps brachii muscle triceps brachii muscle
scalene muscles subclavius muscle
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test. The a level for statistical significance was set at
0.05. All analyses were performed using Systat 12 or Sig-
mastat 3.1 for Windows (Systat Software, Inc. Chicago,
IL, USA).
Results
A flowchart describing patient participation is depicted
in Figure 5. Out of 211 patients who were treated for
shoulder disorders, between September 2007 and
September 2009, 72 patients (50 females and 22 males;
mean age 43.9 years, SD 12.3; 95% CI 41.0 to 46.0) pre-
sented with unilateral, non-traumatic shoulder com-
plaints, met the study inclusion criteria, and agreed to
participate in this study. Twenty-six subjects were suf-
fering from their first episode of shoulder pain, while
for 19 subjects this was their second episode. The
remaining 27 subjects had suffered from ≥ 3 episodes of
shoulder pain. Study participants’ characteristics are
summarized in Table 2. A comparison of data obtained
Consecutive subjects with shoulder 
pain screened for eligibility 
(n= 211) 
 
Subjects 
with unilateral shoulder pain 
(n=75) 
excluded (n=136) 
 
primary frozen shoulder (n=20) 
bilateral shoulder pain (n=26) 
post-traumatic (n=8) 
post-surgical (n=5) 
consultation (n=30) 
<18 years (n=3) 
>65 years (n=8) 
duration of complaints < 6 months (n=8) 
reason unclear (n=15) 
subjects with unilateral non-
traumatic shoulder pain were  
applicable for analysis 
(n=72) 
3 subjects were excluded after physical 
examination, because of signs and 
symptoms of primary frozen shoulder 
(n=2) or severe language problems (n=1).  
Eligible 
(n=88) 
Declined to participate 
(n=13) 
Figure 5 Flow chart showing a schematic summary of patient participation in this study.
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studies is presented in Table 3. The mean age of the
present study population was lower (p <0 . 0 5 )a n dt h e
proportion of female subjects was higher (p < 0.05)
compared to these other studies. In addition, the current
study population was more highly educated (p < 0.05)
than the previous study populations for which educa-
tional data was reported [3,5,52]. Comparison of the
duration of shoulder pain was not possible because dif-
ferent classifications were used.
Prevalence of muscles with myofascial trigger points per
subject
Muscles containing active MTrPs were found in all 72
subjects. The median number of muscles with active
MTrPs per subject was 6 (range 2 to 16). Muscles
containing latent MTrPs were found in 67 subjects. The
median number of muscles with latent MTrPs per sub-
ject was 4 (range 0 to 11). Figure 6 shows the frequency
distribution of active and latent MTrPs per subject.
Neither active MTrPs nor latent MTrPs were normally
distributed (Shapiro W =0 . 9 5 ;p < 0.05; W =0 . 9 6 ;p
<0.05 respectively).
Prevalence of myofascial trigger points by muscle
Active MTrPs were found in the infraspinatus muscle in
56 subjects and in the upper trapezius muscle in 42 sub-
jects. In addition, active MTrPs were highly prevalent in
the middle trapezius (n = 31), anterior deltoid (n = 34),
middle deltoid (n = 36), posterior deltoid (32), and teres
minor (n = 34) muscles.
Latent MTrPs were found in the infraspinatus muscle
in 11 subjects and in the upper trapezius in 27 subjects.
L a t e n tM T r P sw e r ef o u n di nt h et e r e sm a j o rm u s c l ei n
35 subjects and in the anterior deltoid muscle in 27 sub-
jects. Figure 7 presents the distribution of active and
latent MTrPs per muscle.
DASH-DLV, VAS-P, BDI-II-DLV, and PROM
The mean score on the DASH was 30.8 (SD 14.1; 95%
CI 27.5 to 34.1). Mean VAS-P scores were follows: the
VAS-P score for ‘current pain’ (VAS-P1) was 30 (SD
23.9; 95% CI 27.0 to 39.9), for ‘average pain in the last
seven days’ (VAS-P2) was 42.1 (SD 17.7; 95% CI 37.4 to
50.0) and for ‘for the most severe pain in the last seven
days’ (VAS-P3) was 56.6 (SD 19.8; 95% CI 51.2 to 61.9).
The mean PROM score, calculated as the sum the
PROM value measured for the non-affected shoulder
minus the PROM value measured for the affected
shoulder, was 32.4 degrees (SD 34.8; 95% CI 24.2 to
40.6), where a positive value indicates that the affected
shoulder has a impaired range of motion. Both DASH
and PROM scores were normally distributed (W =0 . 9 7 ;
p< 0.05 and W=0.91; p < 0.05 respectively). VAS-P1,
VAS-P2, and VAS-P3 scores were also considered to be
normally distributed, although the Shapiro-Wilk test did
present borderline results for VAS-P2 and VAS-P3.
Correlation between the number of muscles with MTrPs
and pain and disability scores (DASH-DLV, VAS-P)
The number of muscles with active MTrPs only moder-
ately correlated with the DASH-DLV (r = 0.30; p< 0.05)
and VAS-P1 scores (r = 0.33;p < 0.05), and poorly cor-
related with VAS-P2 (r = 0.28; p< 0.05) and the dura-
tion of the shoulder pain (r = 0.26, p< 0.05). We were
unable to detect statistically significant correlations
between the number of muscles with MTrPs (either
active or latent) and VAS-P3 (r = 0.09; p> 0.05) or the
PROM (r =0 . 1 3 ;p> 0.05) scores. Table 4 provides an
overview of the correlations and Figure 8 shows a
Table 2 Characteristics of patients participating in this
study (n = 72)
Characteristics n (%) mean (SD; 95% CI); median
Age (years) 43.9 (12.3; 41.0 - 46.8); 45.0
Gender, female 50 (69.4)
Duration of shoulder pain
6-9 months 17 (23.6)
9-12 months 14 (19.4)
1-2 years 13 (18.0)
2-5 years 14 (19.4)
>5 years 14 (19.4)
Recurrence rate
1
st episode 26 (36.1)
2
nd episode 19 (26.4)
3
rd > episode 27 (37.5)
Hand dominance, left-handed 4 (5.6)
Side of complaints right 48 (66.7)
DASH-DLV (0 - 100)
a 30.8 (14.1; 27.5 - 34.1); 28.3
VAS-P1 (0-100)
b 30.0 (23.9; 27.0 - 39.9); 30.0
VAS-P2 (0-100)
b 42.1 (17.7; 37.4 - 50.0); 40.0
VAS-P3 (0-100)
b 56.6 (19.8; 51.2 - 61.9); 57.0
BDI-II-DLV (0 - 63)
c 6.1 (6.0; 4.7 - 7.6); 5.00
0-13 68 (94.4)
14-19 3 (4.3)
20-28 0 (0.0)
28-63 1 (1.4)
d
a Higher Dash-DLV (Disabilities of the Arm, Shoulder and Hand outcome
measure- Dutch Language Version) scores mean more disability with a
maximum of 100 (range from 0 to 100)[59].
b Higher VAS-P scores (Visual Analogue Scales for Pain) mean more pain, with
a maximum of 100 (range from 0 to 100). VAS-P1 represents the current pain
score, VAS-P2 represents the average pain score over the past seven days,
and VAS-P3 represents the most severe pain score over the past seven days.
c Higher scores on the BDI-II-DLV (Beck Depression Inventory-second edition-
Dutch Language Version) mean more symptoms of depression. Clinical
interpretation of scores is accomplished through criterion-referenced procedures
utilizing the following interpretive ranges: 0-13 minimal depression; 14-19 mild
depression; 20-28 moderate depression; and 29-63 severe depression[79].
d One patient scored 45 points, which is indicative of major depression. This high
score was due to a major event that happened on the day of inclusion in the study.
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Page 6 of 12scatterplot of DASH scores versus the number of active
MTrPs.
Discussion
Prevalence of MTrPs
All subjects with unilateral, chronic, non-traumatic
shoulder pain presented with multiple shoulder muscle
MTrPs. In addition, MTrPs were found in all 17 mus-
cles examined. However, the number of shoulder mus-
cles with MTrPs appeared to vary greatly among
subjects. In particular, MTrPs were most frequently
located in the infraspinatus and upper trapezius muscles,
in agreement with results from Skootsky [37] and
Simons [26], who found that infraspinatus muscles were
frequently associated with myofascial shoulder pain
shoulder. There are very few other prevalence studies in
the literature, and to the best of our knowledge, this is
the first extensive report on the prevalence of MTrPs in
patients with chronic, non-traumatic unilateral shoulder
pain.
Table 3 Socio-demographic characteristics of the current study population and eight other Dutch shoulder research
study populations
Current
study
N=7 2
Van der Windt
1996
N = 335
De Winter
1999
N = 201
Winters
1999
N = 101
Bot
2005
N=
281
Bergman
2005
N=7 1
Kuijpers
2006
N = 492
Feleus
2008
N = 682
Reilingh 2008
N = 587
Age (years,± SD)
43 (12.3) 49.6 (14.4) 48 (12) 47.3 (15.4) 49.2
(13.8)
47.8 (11.8) 52 (14) 45* 49.5 (14.7)† 51.9 (13.9)‡ 52.9
(13.3)¶
Gender (%)
female 69 56 66 58 63 52 50 52 50
Education level
Low 6 NA NA NA 44 NA NA 36 36
Medium 47 NA NA NA 42 NA NA 36 41
High 47 NA NA NA 14 NA NA 28 23
Duration of shoulder pain (month)
< 3 m 0 85 26 75 66 70 60 74 59
3-6 m 16 30 40 41
> 6 m 100 15 55 25 34 26
*Feleus reported the median instead of the mean age
†Mean age (±SD) of the acute pain group (< 6 weeks)
‡Mean age (±SD) of the subacute pain group (6-12 weeks)
¶Mean age (±SD) of the chronic pain group (> 3 months)
NA (not available). It was not possible to derive these data from the papers.
Figure 6 The number of active (black bar) and latent (grey bar)
of MTrPs per subject. The X-axis shows the number of subjects,
and the Y-axis shows the number of MTrPs per subject (n = 72).
Figure 7 The number of subjects with active (black bar) or
latent MTrPs (gray bar) per muscle. The X-axis shows the
muscles that were examined for identification of MTrPs, and the Y-
axis shows the number of subjects with MTrPs (n = 72).
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The mean DASH-DLV score measured for the current
study population is comparable with the mean baseline
scores measured for other study populations for subjects
with shoulder and arm pain [63-65]. According to Bea-
ton[66] subjects (n = 200) with DASH scores < 23.6 are
still able to perform all desired daily activities, although
they may experience some discomfort. For comparison,
in a study population from the US (n = 1706), the mean
DASH score was 10.10 (SD 14.68) and in young active
and healthy adults the mean DASH score was 1.85 (SD
5.99) [67]. Importantly, the DASH-DLV score primarily
reflects the level of dysfunction with less emphasis on
pain and other symptoms. While 23 items refer to the
ability of the subject to perform activities, only 7 items
assesses the severity of symptoms. Subjects with long-
standing shoulder complaints may alter the way in
which they perform activities by using compensatory
movements. In addition, DASH-DLV does not discrimi-
nate between activities performed using the affected or
non-affected arm, which may influence the magnitude
of the disability and therefore the final DASH-DLV
score. In support of this, several subjects in our study
commented that their DASH score would have been dif-
ferent if the activities in question were related to the
affected arm.
Correlation between number of muscles with MTrPs,
DASH-DLV scores, and VAS-P scores
The number of muscles containing active MTrPs mod-
erately and positively correlated with DASH-DLV, VAS-
P1, VAS-P2 scores, and the duration of the shoulder
pain, suggesting that the number of muscles with active
MTrPs explained only 10% of the variation of the out-
come measures, including pain and disability. In addi-
tion, other clinically relevant factors may have
contributed to the primary and secondary outcome
scores. First, although we did not measure the pain
intensity at the MTrP, this may have a significant
impact on pain and functioning. Hidalgo et al found
that patients with shoulder pain had a larger number of
both active and latent MTrPs than healthy subjects.
They also found that active MTrPs were associated with
greater pain intensity, and that lower Pain Pressure
Thresholds (PPT) were reported for active MTrPs com-
pared to latent and patients with shoulder pain dis-
played lower PPT than healthy subjects [49]. Second, in
this study we did not take into consideration the num-
ber of MTrPs per muscle, which may have contributed
to the moderate correlation observed between the num-
ber of muscles with MTrPs and the DASH-DLV and
Table 4 Correlation matrix of the current study population (n = 72)
MTrPs Active MTrPs Latent MTrPs DASHDLV BDI-II DLV VAS P1 VAS P2 VAS P3 Duration
MTrPs - 0.65* 0.11 0.29* 0.22 0.44* 0.31* 0.06 0.26*
AMTrPs - -0.64* 0.30* 0.16 0.33* 0.28* 0.01 0.12
LMTrPs - -0.12 0.02 -0.02 -0.06 0.04 0.04
DASH-DLV - 0.35* 0.66* 0.58* 0.27* 0.05
BDI-II-DLV - 0.33* 0.18 0.07 0.13
VAS-P1 - 0.68* 0.35* 0.18
VAS-P2 - 0.57* 0.18
VAS-P3 - -0.10
Duration -
The data represent Spearman’s rank correlation coefficient. Correlation coefficients between the number of muscles with myofascial trigger points (MTrPs), the
number of muscles with active MTrPs (AMTrPs) and the number of muscles with latent MTrPs (LMTrPs), the DASH (Disability of the Arm, Shoulder and Hand)
outcome measure- Dutch Language Version (DASH-DLV), the Beck Depression Inventory-second version- Dutch language Version (BDI-II-DLV), the Visual Analogue
Scales for current pain (VAS-P1), the average pain over the last seven days (VAS-P2), the most severe pain over the last seven days (VAS-P3) and the duration of
shoulder pain (Duration), are given (* p < 0.05).
Figure 8 Scatterplot of DASH scores versus the number of
muscles with active MTrPs. The regression line shows a weak
positive correlation (r = 0.3), indicating that increasing numbers of
active MTrPs have only a moderate effect on DASH scores.
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was poorly but positively correlated with the duration of
the complaints, indicating that the number of shoulder
muscles with MTrPs may increase over time regardless
of whether the MTrPs were active or latent. Finally,
because one of the characteristics of the DASH-DLV
score is, that it does not discriminate between the
affected and the non-affected shoulder, one could specu-
late that patients with chronic shoulder pain may
develop strategies to overcome pain and disability
caused by their shoulder disorder, for instance by using
the non-affected arm, resulting in decreased DASH-
DLV and VAS-P scores. All these factors may have a
substantial influence on the correlation coefficient.
Although the number of shoulder muscles with active
MTrPs correlates only moderately with the various out-
come measures, this does not imply that MTrPs are
clinically unimportant. Future studies of chronic
shoulder pain examining the total number of trigger
points and their pressure sensitivity in the muscles stu-
died could substantially impact the magnitude of the
effect of presence of myofascial trigger points on
shoulder pain and disability.
Clinical implications
To date, unilateral shoulder pain has mainly been pro-
posed to be due to either the presence of inflammation
in the subacromial tendons and bursae, or degenerative
rotator cuff ruptures (diagnosed using modern imaging
techniques, such as MRI or sonography). Although
these pathological structures may cause pain, it is also
known that similar abnormalities have been found in
asymptomatic shoulders.
Active MTrPs, which are painful spots that produce
familiar shoulder pain during contraction, stretching or
compressing, these MTrPs may provide an alternative
explanation for shoulder pain, which is independent of
the presence of subacromial abnormalities. According to
Simons, Travell and Simons [26], MTrPs within the
infraspinatus muscle (which were most prevalent) cause
pain in the anterior and middle deltoid regions which
expands into the frontal upper arm, as well as referred
pain and referred sensations felt in the wrist and the
hand. In addition, internal rotation and cross-body
adduction may be impaired, which is often the case in
patients with shoulder pain. Both experimentally
induced and spontaneous muscle pain lead to an aber-
rant motor activation pattern that is also present in
patients with shoulder pain [68,69]. Although latent
MTrPs are not usually an im m e d i a t es o u r c eo fp a i n ,
they can elicit referred pain when mechanically stimu-
lated, or during sustained or repeated muscle contrac-
tion. In addition, latent MTrPs may disturb normal
motor recruitment patterns and movement efficiency.
Lucas et al. showed that subjects who received myofas-
cial dry needling, followed by passive muscle stretching
to remove latent MTrPs, showed normalized motor acti-
vation patterns within 20 to 30 minutes following the
treatment [48]. Therefore, it is reasonable to expect that
treatment of MTrPs may lead to normalization of motor
activation patterns and may facilitate spontaneous
recovery of shoulder pain, either without exercising or
by making exercise more effective.
Based on the results of this study, we propose that an
alternative approach may be indicated for the assess-
ment and management of patients with chronic, non-
traumatic shoulder pain. Current treatment regimens
consist primarily of pharmacological interventions,
including anti-inflammatory medications, or muscle
strengthening exercises. If MTrPs are one of the main
reasons for shoulder pain (active MTrPs) and altered
motor activation patterns (active and latent MTrPs), as
several authors have proposed, then anti-inflammatory
treatment [26,48,70] and muscle strengthening exercises
should not be the treatment of first choice. Instead, the
treatment should begin with MTrP inactivation. Manual
techniques, including manual compression of the MTrP,
known as ischemic compression or trigger point release,
trigger point dry needling or injection therapy are used
to inactivate MTrPs. After MTrP inactivation, muscle
stretching and relaxation exercises, heat applications,
dynamic exercises to improve range of motion and mus-
cle reconditioning are instructed as appropriate. This
therapy is accompanied with a gradual increase in daily
activities.
If the above hypothesis is true, treatment of MTrPs
could provide an innovative, promising therapy for
shoulder pain. This study sho w st h er e s u l t so fp a t i e n t s ’
characteristics for a sample of patients with chronic,
unilateral non-traumatic shoulder pain, who were
recruited for a randomized clinical trial to study the
results of MTrPs directed interventions by physical
therapists in this group. The results of this study are
published[71].
General Applicability
We compared sociodemographic data from the current
study population with similar data from several other
Dutch shoulder pain research studies. Because none of
these studies investigated MTrPs, we made this compar-
ison to see whether there was reason to expect that the
high prevalence of MTrPs we observed was unique to
our population. In our study population more females
were included, and the subjects were significantly
younger and more highly educated than subjects from
the other Dutch populations, although a specific expla-
nation for these differences is lacking. There is no rea-
son to suspect that educational levels correlate with the
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mainly important for effectiveness studies, because they
may impact the patients’ motivation and compliance
[72,73]. However, increased age may also be associated
with increased number of MTrPs [74]. Because the sub-
jects of the present study were younger, and musculos-
keletal complaints tend to increase with age [74], there
is no reason to suspect that we overestimated the preva-
lence of MTrPs in our population. On the other hand,
there were more females in our study population, and
females may be more prone to musculoskeletal disorders
in general [75]. Thus, for this reason there may be a
chance that MTrPs were slightly more prevalent in our
study population [76-78]. Despite the above-mentioned
differences, we conclude that our subjects are compar-
able with other patients with chronic shoulder pain and
the findings of this study can be generalized to other
patients.
Strength and limitations of the present study
One of the limitations of our study is that we only
examined patients with unilateral chronic shoulder
pain and dysfunction, whereas MTrPs are thought to
be responsible for both acute and chronic pain. It is
conceivable that patients who developed chronic
s h o u l d e rp a i nm a yh a v em o r eM T r P s ,a n dp e r s i s t e n t
MTrPs in the acute phase than patients who recover
easily. In future research projects assessment of MTrPs
in patients with acute shoulder problems should also
be included. The small sample size is another limita-
tion of this study. Before starting this study a power
analysis was performed and it was calculated that 104
subjects would be needed for the clinical trial. After
two years (one year more than originally planned, 72
subjects were enrolled in the study. For practical rea-
sons, the study was completed with this smaller sample
size, which may have influenced some of the results of
this study. We used two observers in this study with
identical clinical experience and post-graduate training
on myofascial trigger point therapy. In addition, both
observers found a comparable mean number of active
MTrPs. Because there was no statistically significant
difference in mean DASH scores obtained by the two
observers, we consider both groups to be comparable
and the findings obtained by both observers to be
similar.
Conclusions
T h i ss t u d yd e m o n s t r a t e st h a tM T r P sa r ev e r yp r e v a l e n t
in patients with chronic unilateral, non-traumatic
shoulder pain. In addition, the number of MTrPs is only
moderately correlated with DASH-DLV outcome mea-
sures and VAS-P pain measures, indicating that MTrPs
contribute to the clinical picture of common shoulder
pain problems. We recommend that the MTrP examina-
tion and treatment should be considered for patients
with shoulder pain in both future clinical studies and
clinical practice.
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